UAE Health Ministry Approves Biomerica's Kidney Disease Test

Biomerica, Inc., a company specializing in advanced diagnostic solutions, has achieved a significant milestone with the approval of its Fortel® Kidney Disease Test by the Ministry of Health and Prevention in the United Arab Emirates (UAE). This authorization allows Biomerica to market its innovative kidney disease diagnostic tool throughout the UAE, a region facing significant challenges related to chronic kidney disease (CKD).

The Fortel® Kidney Disease Test is designed to quickly and easily detect early signs of kidney damage by identifying low levels of microalbumin in urine samples. Providing results within just 10 minutes, this test is particularly useful for early detection of kidney disease, enabling healthcare providers to intervene before substantial damage occurs. Such early detection is crucial as CKD often goes unnoticed due to its lack of symptoms in initial stages. The condition is especially prevalent among individuals with diabetes, hypertension, obesity, and older adults, placing these groups at higher risk. Despite the widespread nature of CKD, more than 80% of those at risk remain undiagnosed, contributing to its status as a global public health issue.

Addressing CKD promptly has the potential to prevent its progression to end-stage renal disease, which often necessitates dialysis or a kidney transplant. In addition to improving health outcomes, early intervention can significantly reduce the economic costs associated with the disease's advancement. Globally, CKD is projected to become the fifth leading cause of life-years lost by 2040.

In the UAE, diabetes and hypertension are the primary contributors to CKD, affecting a substantial portion of the population. The International Diabetes Federation reports that over 12% of UAE adults have diabetes, with regional studies indicating that 29% to 35% suffer from hypertension. These conditions often lead to CKD, which is frequently undetected until severe kidney damage has occurred. The Fortel® Kidney Disease Test aims to facilitate earlier diagnosis, enabling better management and treatment options for at-risk individuals.

Zack Irani, CEO of Biomerica, emphasized the importance of this test in preventative healthcare. He highlighted the high prevalence of diabetes and hypertension in the UAE, reinforcing the need for effective diagnostic tools to identify kidney disease before symptoms manifest. This approval aligns with Biomerica's mission to deliver vital healthcare solutions to regions where they are most needed.

Biomerica's expansion into the UAE market builds on its established presence in the Middle East, where it has already introduced successful diagnostic products such as the EZ Detect™ Colon Disease Test. The company has partnered with major distributors and healthcare providers to ensure the availability of the Fortel® Kidney Disease Test across the country.

Biomerica is committed to offering accessible, high-quality diagnostic products that empower both patients and healthcare professionals. The Fortel® Kidney Disease Test is part of a comprehensive range of solutions aimed at improving patient outcomes through early detection and personalized care strategies.